main content start

Homepage

Latest Videos

Latest Videos

Brightcove Home Latest Listing

Breast Cancer

Breast Cancer

Brightcove Cards Listing

Prostate Cancer

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • Myelodysplastic Syndromes14m 13s

    ASH 2022 Update on Myelodysplastic Syndromes

    ASH 2022 - Update on Myelodysplastic Syndromes
    low risk mds eln classification low dose lenalidomide viale -a tags: azacitidine venetoclax
  • Breast Cancer3m 56s

    Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission

    There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
    her2 positive mbc prolonged remission trastuzumab duration
  • Myelodysplastic Syndromes7m 3s

    Clinical Application of Web Based Tool for Improving MDS Diagnosis

    Gradient Based Model based on 10 routinely used parameters (Age, Gender, Hb, WBC, MCV, Platelets, Neutrophils, Monocytes, Glucose, Creatinine) is now available to facilitate non-invasive diagnosis of MDS.
    mds non-invasive diagnosis
  • Breast Cancer14m 46s

    ESMO 2022 Breast Cancer Comprehensive Coverage

    View comprehensive coverage of Breast Cancer from ESMO 2022
    dose dense adjuvant chemotherapy esmo keynote -522 monarch -3 study
  • Breast Cancer8m 50s

    Immunotherapy of Early Breast Cancer

    I-SPY2 clinical trial laid the foundation for Immunotherapy in Early Breast Cancer with Pembrolizumab added to Neoadjuvant Chemotherapy.
    keynote -522 immunotherapy early breast cancer
  • Breast Cancer11m 14s

    Oral Selective Estrogen Receptor Degraders for ESR-1 Mutant Metastatic Breast Cancer

    Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.
    biomarkers esr1 mutation fulvestrant hormone receptor positive mbc serd
  • OncoSpecials7m 52s

    Treatment Free Remission in CML - Ready for Prime Time

    TFR strategy is generally safe with adequate monitoring. Restarting TKI after loss of Major Molecular Response is safe with 80% of patients regaining MR4 after restarting TKI treatment.
    treatment free remission tfr dasatinib
  • Multiple Myeloma4m 12s

    Key Practice Points -Myeloma Related Renal Impairment

    In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
    myeloma renal impairment key practice points
  • Pharmacy37m 20s

    Quality management systems in pharmacy practice

    Dr Scott Soefje, PharmD, Mayo Clinic
    Provides a perspective “Quality Management Systems in Pharmacy Practice”.
    mednrich
  • Multiple Myeloma6m 23s

    Bone Targeted Treatments in Multiple Myeloma 2024-03-VD-EM-MMY-07

    Long-term usage of bisphosphonates should be balanced with the potential of possible side-effects. Watch the detailed video on MedEnrich to learn about use of bone targeted agents, its dosage, frequency, optimal usage and limitations.
    bisphosphonates convenient agent bone lesions side-effects
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing

    Webinars

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback